1. Reasons patients were excluded from the switch from atorvastatin to simvastatin
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

2. Outcome of patients originally being prescribed 10 or 20 mg atorvastatin
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

3. Total serum cholesterol before and after switching from atorvastatin to simvastatin
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

4. Total cholesterol before (closed diamonds) and after (open squares) switching from atorvastatin to simvastatin - Dotted line marks audit standard
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

5. Reasons patients were excluded from the switch from losartan to candesartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

6. Reasons patients were switched back to losartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

7. Outcome of patients originally being prescribed losartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

8. Blood pressure before and after switching from losartan to candesartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

9. Systolic and diastolic blood pressure recordings before (closed diamonds) and after (open squares) switching from losartan to candesartan for patients without diabetes or cardiovascular disease (CVD; A), with diabetes (B) and with CVD (C). Dotted lines indicated audit standard
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23

10. Outcome Representative sample of respondents’ comments on how they felt when they were asked to change their medication
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23